The discovery and implementation of immunomodulatory drugs (IMiD® s) has revolutionized
the treatment of many hematological malignancies due to the plethora of IMiD®-induced …

The protein cereblon (CRBN) is a substrate receptor of the cullin 4-really interesting new
gene (RING) E3 ubiquitin ligase complex CRL4 CRBN. Targeting CRBN mediates selective …

Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in
hematological malignancies. The ubiquitously expressed E3 ligase protein cereblon …

Abstract Characterization of RING finger E3-Ubiquitin Ligase Cereblon in Hematopoietic
Regulation Cereblon is a RING-domain E3 ubiquitin ligase (UbL) that is the direct protein …

Thalidomide was first developed as a sedative around 60 years ago, but exhibited
teratogenicity, leading to serious defects such as limb deformities. Nevertheless, thalidomide …

Immunomodulatory drugs (IMiDs), today also known as cereblon (CRBN) binding drugs, are
therapeutically important anti-cancer and anti-inflammatory drugs. IMiDs are analogs of their …

Upon binding to thalidomide and other immunomodulatory drugs, the E3 ligase substrate
receptor cereblon (CRBN) promotes proteosomal destruction by engaging the DDB1 …

Biological Target. Cereblon (CRBN) Summary. Cereblon (CRBN) is a multifunctional protein
located in the cytoplasm, nucleus, and peripheral membrane of the human brain and other …

Despite the pervasive use of the immunomodulatory drugs (IMiDs), thalidomide,
lenalidomide, and pomalidomide, over the past 5 to 15 years for the management of multiple …

The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide are all
approved for the treatment of multiple myeloma. IMiDs bind cereblon (CRBN), a substrate …